Medical Professionals
Publications

Publications: Our research

Filter

Filter

Clear filter
Research Area
Technology
Resource type
Category
157 results found
Dec 12, 2024
Publication
Novavax led
Human Vaccines & Immunotherapeutics
COVID-19
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M™ adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa...
Vivek Shinde, Anthonet Lombard Koen , Zaheer Hoosain, et al.
View
Dec 5, 2024
Publication
Novavax led
Vaccine
COVID-19
Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST)
Anthony M. Marchese, Hadi Beyhaghi, Matthew D. Rousculp, et al.
View
Nov 27, 2024
Preprint
Novavax led
medRxiv
COVID-19
Real-world effectiveness of NVX-CoV2373 and BNT162b2 mRNA COVID-19 vaccination in South Korea
Eunseon Gwak, Seung-Ah Choe, Kyuwon Kim, et al.
View
Nov 26, 2024
Preprint
Novavax led
Preprint
COVID-19
Cost-Effectiveness of Introducing Nuvaxovid to COVID-19 Vaccination in the United Kingdom: Dynamic Transmission Model
Clive Pritchard, Lucie Kutikova, Richard Pitman, et al.
View
Nov 23, 2024
Preprint
Novavax led
bioRxiv
Seasonal influenza, Matrix-M™ adjuvant
Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M nanoparticle vaccine induces neutralizing responses in nonhuman primates.
Nita Patel, Asma Rehman, Jessica F. Trost, et al.
View
Nov 19, 2024
Publication
Novavax led
microorganisms
Seasonal influenza, Matrix-M™ adjuvant
A Modified Novel Validated High-Throughput Hemagglutinin Inhibition Assay Using Recombinant Virus-like Particles and Human Red Blood Cells for the Objective Evaluation of Recombinant Hemagglutinin Nanoparticle Seasonal Influenza Vaccine.
Timothy S. Vincent, Mingzhu Zhu, Anand Parekh, et al.
View
Nov 11, 2024
Preprint
Novavax led
medRxiv
COVID-19, Matrix-M™ adjuvant
Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: a phase 3, randomized, placebo-controlled trial (PREVENT-19)
Germán Añez, Alice McGarry, Wayne Woo, et al.
View
Nov 9, 2024
Publication
Novavax led
ScienceDirect
COVID-19, Matrix-M™ adjuvant
Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea
Eunseon Gwak, Seung-Ah Choe, Erdenetuya Bolormaa, et al.
View
Nov 8, 2024
Preprint
Novavax led
medRxiv
COVID-19, Matrix-M™ adjuvant
Adjuvant Recombinant SARS-CoV-2 Spike Protein Vaccine Immunogenicity After Prior mRNA Vaccine Doses
Jeffrey M Adelglass, Paul Bradley, Miranda R Cai et al.
View
Nov 8, 2024
Preprint
Novavax led
medRxiv
COVID-19, Matrix-M™ adjuvant
Safety and Immunogenicity of Omicron Protein Vaccines in mRNA-Vaccinated Adolescents: A Phase 3, Randomised Trial
Chijioke Bennett, Gordon Chau, Erika Clayton et al.
View